Sana Biotechnology (SANA) Debt Ratio (2021 - 2026)

Sana Biotechnology (SANA) reported Debt Ratio of 0.14 for Q1 2026, up 48.66% sequentially from 0.1 in Q4 2025.

Sana Biotechnology (SANA) Debt Ratio (2021 - 2026) Analysis & Trends

Sana Biotechnology (SANA) has 5 years of Debt Ratio data on file, last reported at 0.14 in Q1 2026.

  • For the quarter ending Q1 2026, Debt Ratio changed N/A year-over-year to 0.14; the trailing twelve-month figure through Mar 2026 stood at 0.14 (changed N/A YoY), and the FY2025 full-year result was 0.1, changed N/A from the prior year.
  • Debt Ratio rose to 0.14 in Q1 2026, from 0.1 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.14 in Q1 2026 to a low of 0.05 in Q1 2022.
  • A 4-year average of 0.08 and a median of 0.07 in 2023 frame the typical range for Debt Ratio.
  • Peak annual rise in Debt Ratio reached 87.7% in 2022, while the deepest fall reached 47.87% in 2022.
  • Tracing SANA's Debt Ratio over 4 years: stood at 0.07 in 2022, then gained by 22.8% to 0.08 in 2023, then increased by 16.73% to 0.1 in 2025, then surged by 48.66% to 0.14 in 2026.
  • Business Quant data shows SANA's Debt Ratio at 0.14 in Q1 2026, 0.1 in Q4 2025, and 0.08 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 1.41
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.11
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.05
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Sana Biotechnology 888.71 Mn 888.71 Mn - 0.14

Historic Data

Download Data
DateValue
Mar 31, 2026 0.14
Dec 31, 2025 0.10
Jun 30, 2023 0.08
Mar 31, 2023 0.08
Dec 31, 2022 0.07
Sep 30, 2022 0.07
Jun 30, 2022 0.05
Mar 31, 2022 0.05
Dec 31, 2021 0.05
Sep 30, 2021 0.04